[{"Assets_0_Q2_USD":3298858.0,"CommonStockSharesOutstanding_0_Q2_shares":29764210.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-4818845.0,"NetIncomeLoss_1_Q2_USD":-7129310.0,"NetIncomeLoss_2_Q2_USD":-10509403.0,"StockholdersEquity_0_Q2_USD":1434681.0,"EarningsPerShareBasic_1_Q2_USD":-0.28,"EarningsPerShareBasic_2_Q2_USD":-0.55,"Ticker":"RLMD","CIK":"1553643","name":"RELMADA THERAPEUTICS, INC.","OfficialName":"Relmada Therapeutics Inc. Common Stock","form":"10-Q","period":"20181231","fy":"2019.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"772606380.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20190213"}]